Study by Dr Moran and her colleagues shows that PPPs have been a essential driver of this considerable upsurge in activity, and that the PPP approach brings together the best skills of both open public and private partners. This model therefore performs better than either sector working by itself with regards to delivering secure, effective, affordable medications for neglected diseases. In a linked editorial, entitled A FRESH Era of Expect the World’s Most Neglected Illnesses , the PLoS Medicine editors argue that Moran’s results are one of several indicators that the world is finally taking action against these illnesses..For further study information, please visit With the initiation of this trial, we have three targeted oncology today therapeutic candidates in medical development, which use distinct and novel mechanisms of action to fight cancer, said William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO. The successful advancement of AV-203 in to the clinic and the identification of a potential biomarker of AV-203 response provide additional validation of the benefits of our proprietary Human being Response Platform. .. 4SC 2010 first 9 months revenue decreases from EUR1.4 million to EUR0.8 million 4SC , a medication discovery and development firm focused on autoimmune and malignancy indications, today announced its economic results in accordance with International Financial Reporting Specifications for the first nine months of 2010, which ended on 30 September 2010.